Loading...

Meyskens, Frank L.

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentMedicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The 19th Annual Meeting of the Pan American Society for Pigment Cell Research Conference
    NIH/NIAMS R13AR068914Aug 1, 2015 - Jul 31, 2016
    Role: Principal Investigator
    SWOG NCORP Research Base
    NIH/NCI UG1CA189974Aug 1, 2014 - Jul 31, 2019
    Role: Co-Principal Investigator
    7th International Conference on Clinical Cancer Prevention 2012 with Consensus Co
    NIH/NCI R13CA171707Mar 1, 2013 - Feb 28, 2014
    Role: Principal Investigator
    PanAmerican Society for Pigment Cell Research (PASPCR)
    NIH/NCI R13CA110471Jul 16, 2004 - Jul 15, 2005
    Role: Principal Investigator
    Phase I and II Clinical Trials of Agents for Cancer Prevention
    NIH/NCI N01CN35160Sep 30, 2003 - Sep 29, 2009
    Role: Co-Principal Investigator
    Phase III Colon Cancer Prevention Trial
    NIH/NCI R01CA088078Sep 30, 2002 - Aug 31, 2010
    Role: Principal Investigator
    CHEMOPREVENTION OF FAMILIAL PROSTATE CANCER
    NIH/NCI U19CA081886Sep 30, 1999 - Sep 30, 2007
    Role: Principal Investigator
    PHASE II CLINICAL TRIAL OF TOPICAL POLYPHENON E
    NIH/NCI N01CN085182Sep 30, 1998
    Role: Principal Investigator
    Chemoprevention of Oral Cancer with BBIC
    NIH/NCI U01CA072294Mar 14, 1997 - Aug 31, 2010
    Role: Principal Investigator
    PHASE II CLINICAL TRIAL OF DFMO AND NSAIDIN COLON - WORKSTATEMENT 45 -261075019
    NIH/NCI N01CN075019Feb 15, 1997 - Feb 15, 2002
    Role: Co-Principal Investigator
    SIXTEEN INTERNATIONAL PIGMENT CELL CONFERENCE
    NIH/NCI R13CA072887Sep 30, 1996 - Sep 29, 1997
    Role: Principal Investigator
    CLIN CTR CLINICAL TRIAL/OBSERVATIONAL STUDY OF WHI
    NIH/WHI N01WH042107Sep 30, 1994 - Sep 14, 2005
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA062203Aug 15, 1994 - Jan 31, 2021
    Role: Co-Principal Investigator
    SOUTHWEST ONCOLOGY GROUP
    NIH/NCI U10CA058723Aug 1, 1993 - Dec 31, 1997
    Role: Principal Investigator
    POLYAMINE DEPLETION AND CHEMOPREVENTION OF COLON CANCER
    NIH/NCI R01CA059024May 1, 1993 - Feb 28, 1998
    Role: Principal Investigator
    CARET--THE CAROTENE AND RETINOL EFFICACY TRIAL
    NIH/NCI U01CA052596Aug 22, 1991 - Jun 30, 1999
    Role: Principal Investigator
    CHEMOPREVENTION EFFICACY TRIAL OF BETA CAROTENE/RETINOL
    NIH/NCI R01CA052596Aug 22, 1991 - Jun 30, 1995
    Role: Principal Investigator
    CHEMOPREVENTION OF HUMAN MELANOMA
    NIH/NCI U01CA051610Jun 1, 1989 - May 31, 1992
    Role: Principal Investigator
    CHEMOPREVENTION OF HUMAN CANCER
    NIH/NCI R13CA046424Jan 1, 1988 - Dec 31, 1988
    Role: Principal Investigator
    Colon Cancer Prevention Program Project Grant
    NIH/NCI P01CA041108Sep 30, 1986 - Jul 31, 2011
    Role: Co-Principal Investigator
    MODULATION AND MEDIATION OF CANCER BY VITAMINS
    NIH/NCI R13CA038506Feb 6, 1985 - Feb 5, 1986
    Role: Principal Investigator
    SWOG Community Clinical Oncology Program Research Base
    NIH/NCI U10CA037429Sep 30, 1983 - May 31, 2015
    Role: Co-Principal Investigator
    Chemoprevention of Skin Cancer Program Project
    NIH/NCI P01CA027502Jul 22, 1980 - Jun 30, 2016
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst. 2018 Oct 27. PMID: 30371800.
      View in: PubMed
    2. Laquer V, Dellinger RW, Mannering I, Garcia AG, Abraham V, Pavlis J, Liu-Smith F, De Feraudy S, Meyskens FL, Kelly KM. 12-hydroxyeicosatetraenoic acid (12-HETE) levels are increased in Actinic Keratoses (AK) and Squamous Cell Carcinoma (SCC). J Am Acad Dermatol. 2018 Jun 11. PMID: 29902547.
      View in: PubMed
    3. Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL, Liu-Smith F, Filipp FV. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. BMC Syst Biol. 2018 Apr 04; 12(1):33. PMID: 29615030.
      View in: PubMed
    4. Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL, Andresen BT, Huang Y. Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. Cancer Prev Res (Phila). 2017 Oct; 10(10):598-606. PMID: 28912118.
      View in: PubMed
    5. Meyskens FL, Liu-Smith F. Redox-Redux and NADPH Oxidase (NOX): Even More Complicated than We Thought it Might Be. J Invest Dermatol. 2017 Jun; 137(6):1208-1210. PMID: 28532757.
      View in: PubMed
    6. Meyskens FL. What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA. J Natl Cancer Inst. 2016 Dec; 108(12). PMID: 27986883.
      View in: PubMed
    7. Liu-Smith F, Krasieva TB, Liu J, Liu J, Meyskens FL. Measuring Redox Status of Melanoma Cells. Methods Mol Biol. 2016 Apr 10. PMID: 27062599.
      View in: PubMed
    8. Dellinger RW, Meyskens FL. Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells. Methods Mol Biol. 2016 Jan 20. PMID: 26786882.
      View in: PubMed
    9. Meyskens FL. Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals. Cancer Prev Res (Phila). 2016 Jan; 9(1):11-2. PMID: 26701663.
      View in: PubMed
    10. Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst. 2016 Feb; 108(2). PMID: 26547931; PMCID: PMC4907357 [Available on 02/01/17].
    11. Fabian CJ, Meyskens FL, Bajorin DF, George TJ, Jeter JM, Khan S, Tyne CA, William WN. Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. J Clin Oncol. 2016 Jan 10; 34(2):186-93. PMID: 26527778.
      View in: PubMed
    12. Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL, Wade JL, Hershman DL. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. J Acupunct Meridian Stud. 2015 Jun; 8(3):152-8. PMID: 26100070; PMCID: PMC4705910.
    13. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 05; 372(10):923-32. PMID: 25738668; PMCID: PMC4405231.
    14. Liu-Smith F, Poe C, Farmer PJ, Meyskens FL. Amyloids, melanins and oxidative stress in melanomagenesis. Exp Dermatol. 2015 Mar; 24(3):171-4. PMID: 25271672; PMCID: PMC4507564.
    15. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep; 7(9):886-95. PMID: 24961880.
      View in: PubMed
    16. Dellinger RW, Liu-Smith F, Meyskens FL. Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis. J Photochem Photobiol B. 2014 Sep 05; 138:317-23. PMID: 25022944; PMCID: PMC4230791.
    17. Liu-Smith F, Dellinger R, Meyskens FL. Updates of reactive oxygen species in melanoma etiology and progression. Arch Biochem Biophys. 2014 Dec 01; 563:51-5. PMID: 24780245; PMCID: PMC4209333.
    18. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1494-504. PMID: 24732629; PMCID: PMC4119495.
    19. Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014 May; 7(5):496-504. PMID: 24614012; PMCID: PMC4208700.
    20. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014 Mar; 106(3):djt456. PMID: 24563519; PMCID: PMC3975165.
    21. Meyskens FL, Simoneau AR, Gerner EW. Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine. Recent Results Cancer Res. 2014; 202:115-20. PMID: 24531785.
      View in: PubMed
    22. Dellinger RW, Garcia AM, Meyskens FL. Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab Pharmacokinet. 2014; 29(2):112-9. PMID: 23965644; PMCID: PMC4487664.
    23. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013 Aug 07; 105(15):1132-41. PMID: 23843441; PMCID: PMC3735464.
    24. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013 May; 6(5):410-8. PMID: 23639862; PMCID: PMC3730525.
    25. Xie L, Meyskens FL. The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines. Melanoma Res. 2013 Apr; 23(2):102-13. PMID: 23344158; PMCID: PMC4077197.
    26. Liu F, Bessonova L, Taylor TH, Ziogas A, Meyskens FL, Anton-Culver H. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res. 2013 Jan; 26(1):128-35. PMID: 23095171; PMCID: PMC4028153.
    27. Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. PLoS One. 2012; 7(10):e47696. PMID: 23110092; PMCID: PMC3478267.
    28. Liu F, Gomez Garcia AM, Meyskens FL. NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. J Invest Dermatol. 2012 Aug; 132(8):2033-41. PMID: 22513785.
      View in: PubMed
    29. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12; 306(14):1549-56. PMID: 21990298; PMCID: PMC4169010.
    30. Chu DZ, Hussey MA, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer. 2011 Dec; 10(4):310-6. PMID: 21782524; PMCID: PMC4286321.
    31. Meyskens FL, Gerner EW. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach. Cancer Prev Res (Phila). 2011 May; 4(5):628-32. PMID: 21543341; PMCID: PMC3574813.
    32. Meyskens FL. Therapeutic prevention of colorectal carcinogenesis. J Carcinog. 2011; 10:13. PMID: 21712960; PMCID: PMC3122104.
    33. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011 Mar; 4(3):354-64. PMID: 21372035; PMCID: PMC4136551.
    34. Meyskens FL, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila). 2011 Mar; 4(3):311-23. PMID: 21372031; PMCID: PMC3059243.
    35. Meyskens FL, Yang S. Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in point. Recent Results Cancer Res. 2011; 188:65-74. PMID: 21253789.
      View in: PubMed
    36. Meyskens FL, McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst. 2010 Dec 15; 102(24):1815-7. PMID: 21115881.
      View in: PubMed
    37. Garcia AM, McLaren CE, Meyskens FL. Melanoma: is hair the root of the problem? Pigment Cell Melanoma Res. 2011 Feb; 24(1):110-8. PMID: 20880199; PMCID: PMC3768291.
    38. Liu F, Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL. MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Mol Cancer. 2010 Aug 11; 9:214. PMID: 20701798; PMCID: PMC2928201.
    39. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, Hayes DF, Hooks J, Ling C, Meyskens FL, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR, Vikram B, Zelefsky MJ, Baker LH. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. Clin Cancer Res. 2009 Sep 15; 15(18):5663-70. PMID: 19723641; PMCID: PMC2978526.
    40. Meyskens FL. Food extracts for chemoprevention: quo vadis? Cancer Prev Res (Phila). 2009 Jul; 2(7):608-10. PMID: 19584073.
      View in: PubMed
    41. Gerner EW, Meyskens FL. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 2009 Feb 01; 15(3):758-61. PMID: 19188144; PMCID: PMC2666541.
    42. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51. PMID: 19066370; PMCID: PMC3682779.
    43. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther. 2008 Dec; 7(12):3751-60. PMID: 19074850.
      View in: PubMed
    44. McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila). 2008 Dec; 1(7):514-21. PMID: 19139001.
      View in: PubMed
    45. Liu F, Fu Y, Meyskens FL. MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J Invest Dermatol. 2009 Feb; 129(2):422-31. PMID: 18971960; PMCID: PMC4321967.
    46. Yang S, Misner B, Chiu R, Meyskens FL. Common and distinct mechanisms of different redox-active carcinogens involved in the transformation of mouse JB6P+ cells. Mol Carcinog. 2008 Jul; 47(7):485-91. PMID: 18092320; PMCID: PMC4587534.
    47. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8. PMID: 18841250; PMCID: PMC2562024.
    48. Gidanian S, Mentelle M, Meyskens FL, Farmer PJ. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake--a basis for the pro-oxidant state of melanoma. Photochem Photobiol. 2008 May-Jun; 84(3):556-64. PMID: 18331399.
      View in: PubMed
    49. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):292-9. PMID: 18268112; PMCID: PMC2515594.
    50. Meyskens FL, Berwick M. UV or not UV: metals are the answer. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):268-70. PMID: 18268109.
      View in: PubMed
    51. Ngo-Metzger Q, August KJ, Srinivasan M, Liao S, Meyskens FL. End-of-Life care: guidelines for patient-centered communication. Am Fam Physician. 2008 Jan 15; 77(2):167-74. PMID: 18246886.
      View in: PubMed
    52. Meyskens FL. Another negative chemoprevention trial: what can we learn? Clin Cancer Res. 2008 Jan 01; 14(1):2-3. PMID: 18172244.
      View in: PubMed
    53. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008 Jan 01; 26(1):66-75. PMID: 18165642.
      View in: PubMed
    54. Yang S, Misner BJ, Chiu RJ, Meyskens FL. Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells. Carcinogenesis. 2007 Nov; 28(11):2382-90. PMID: 17566060.
      View in: PubMed
    55. Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW, Meyskens FL. Development of a polyamine database for assessing dietary intake. J Am Diet Assoc. 2007 Jun; 107(6):1024-7. PMID: 17524725; PMCID: PMC2848593.
    56. Meyskens F. Cancer following total joint arthroplasty. Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):356. PMID: 17301272.
      View in: PubMed
    57. Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007 Feb 01; 13(3):789-94. PMID: 17289868.
      View in: PubMed
    58. Ghajar CM, Suresh V, Peyton SR, Raub CB, Meyskens FL, George SC, Putnam AJ. A novel three-dimensional model to quantify metastatic melanoma invasion. Mol Cancer Ther. 2007 Feb; 6(2):552-61. PMID: 17267658.
      View in: PubMed
    59. Meyskens FL, Farmer PJ, Yang S, Anton-Culver H. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res. 2007; 174:191-5. PMID: 17302196.
      View in: PubMed
    60. Meyskens FL. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2038-41. PMID: 17119025.
      View in: PubMed
    61. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      View in: PubMed
    62. Meyskens FL, Ransohoff DF. Predicting risk for the appearance of melanoma. J Clin Oncol. 2006 Aug 01; 24(22):3522-3. PMID: 16728487.
      View in: PubMed
    63. Goding C, Meyskens FL. Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. Clin Cancer Res. 2006 Feb 15; 12(4):1069-73. PMID: 16489058.
      View in: PubMed
    64. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther. 2005 Dec; 4(12):1923-35. PMID: 16373707.
      View in: PubMed
    65. Meyskens FL, Tully P. Principles of cancer prevention. Semin Oncol Nurs. 2005 Nov; 21(4):229-35. PMID: 16293510.
      View in: PubMed
    66. Meyskens FL, Hietanen P, Tannock IF. Talking to a patient. J Clin Oncol. 2005 Jul 01; 23(19):4463-4. PMID: 15994158.
      View in: PubMed
    67. Meyskens FL, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1366-9. PMID: 15941942.
      View in: PubMed
    68. McEligot AJ, Yang S, Meyskens FL. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu Rev Nutr. 2005; 25:261-95. PMID: 16011468.
      View in: PubMed
    69. Meyskens FL, Szabo E. How should we move the field of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res. 2005; 166:113-24. PMID: 15648187.
      View in: PubMed
    70. Meyskens FL, Farmer PJ, Anton-Culver H. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev. 2005 Jan; 14(1):293. PMID: 15668513.
      View in: PubMed
    71. Cen D, Brayton D, Shahandeh B, Meyskens FL, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004 Dec 30; 47(27):6914-20. PMID: 15615540.
      View in: PubMed
    72. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev. 2004 Dec; 13(12):1996-2002. PMID: 15598753.
      View in: PubMed
    73. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL, Omenn GS, Valanis B, Williams JH. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004 Dec 01; 96(23):1743-50. PMID: 15572756.
      View in: PubMed
    74. Yang S, Meyskens FL. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol Pharmacol. 2005 Jan; 67(1):298-308. PMID: 15492115.
      View in: PubMed
    75. Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004 Oct; 4(10):781-92. PMID: 15510159.
      View in: PubMed
    76. Meyskens FL, Fetting JH. Pulling the trigger. J Clin Oncol. 2004 Sep 01; 22(17):3644-5. PMID: 15337815.
      View in: PubMed
    77. Meyskens FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res. 2004 Apr 15; 10(8):2581-3. PMID: 15102657.
      View in: PubMed
    78. McNulty SE, del Rosario R, Cen D, Meyskens FL, Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004 Apr; 17(2):173-80. PMID: 15016307.
      View in: PubMed
    79. Yang S, McNulty S, Meyskens FL. During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. Pigment Cell Res. 2004 Feb; 17(1):74-83. PMID: 14717848.
      View in: PubMed
    80. Follen M, Meyskens FL, Alvarez RD, Walker JL, Bell MC, Storthz KA, Sastry J, Roy K, Richards-Kortum R, Cornelison TL. Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer. 2003 Nov 01; 98(9 Suppl):2044-51. PMID: 14603541.
      View in: PubMed
    81. Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope. 2003 Oct; 113(10):1687-702. PMID: 14520092.
      View in: PubMed
    82. Chu DZ, Chansky K, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman SM. Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. Ann Surg Oncol. 2003 Oct; 10(8):870-5. PMID: 14527904.
      View in: PubMed
    83. Armstrong WB, Taylor TH, Meyskens FL. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):589-92. PMID: 12869395.
      View in: PubMed
    84. Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL. Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res. 2003 Jun; 16(3):273-9. PMID: 12753401.
      View in: PubMed
    85. Meyskens FL. Management of human melanoma: what has the last decade wrought? Oncologist. 2003; 8(5):448-50. PMID: 14530497.
      View in: PubMed
    86. Follen M, Vlastos AT, Meyskens FL, Atkinson EN, Schottenfeld D. Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes Control. 2002 Nov; 13(9):855-73. PMID: 12462551.
      View in: PubMed
    87. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther. 2002 Jan; 1(3):197-204. PMID: 12467214.
      View in: PubMed
    88. Meyskens FL. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann N Y Acad Sci. 2001 Dec; 952:116-23. PMID: 11795430.
      View in: PubMed
    89. Meyskens FL, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med. 2001 Sep 15; 31(6):799-808. PMID: 11557318.
      View in: PubMed
    90. Meyskens FL, Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma. Pigment Cell Res. 2001 Jun; 14(3):148-54. PMID: 11434561.
      View in: PubMed
    91. Meyskens FL. Cancer prevention in the year 2025: an anticipation. Eur J Cancer. 2000 Sep; 36(14):1737-40. PMID: 10974620.
      View in: PubMed
    92. Meyskens FL. Cancer population genetics and tumour prevention: an unfulfilled paradigm. Eur J Cancer. 2000 Jun; 36(10):1189-92. PMID: 10882855.
      View in: PubMed
    93. Meyskens FL. Criteria for implementation of large and multiagent clinical chemoprevention trials. J Cell Biochem Suppl. 2000; 34:115-20. PMID: 10762023.
      View in: PubMed
    94. Meyskens FL, Buckmeier JA, McNulty SE, Tohidian NB. Activation of nuclear factor-kappa B in human metastatic melanomacells and the effect of oxidative stress. Clin Cancer Res. 1999 May; 5(5):1197-202. PMID: 10353757.
      View in: PubMed
    95. Meyskens FL, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999 May; 5(5):945-51. PMID: 10353725.
      View in: PubMed
    96. Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst. 1998 Aug 19; 90(16):1212-8. PMID: 9719082.
      View in: PubMed
    Frank's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _